# CCB Deputy Director Miles Named Acting Executive Director > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-regulatory-oversight-continuity-nevada-leadership/ > **Published:** 2026-03-20T19:48:25-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:43:00-04:00 > **Clinical Summary:** Explore cannabis regulatory oversight continuity with Nevada's leadership change ensuring stable medical cannabis program operations and patient access. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Policy[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) ProgramRegulatory AffairsPatient AccessNevada Why This Matters Leadership changes at state cannabis control boards directly impact medical cannabis program operations, patient access pathways, and regulatory compliance requirements that affect clinical practice. Continuity in regulatory oversight is essential for maintaining stable medical cannabis supply chains and consistent product testing standards. Clinical Summary Nevada’s Cannabis Compliance Board has appointed Deputy Director Miles as Acting Executive Director, representing a leadership transition within the state’s cannabis regulatory framework. This internal promotion suggests continuity in existing regulatory approaches while the board manages ongoing oversight of both medical and adult-use cannabis operations. The appointment occurs amid ongoing state-level cannabis policy implementation across multiple jurisdictions. Dr. Caplan’s Take “Internal regulatory appointments typically mean less disruption to existing medical cannabis programs than external hires. For Nevada patients and clinicians, this should translate to continued program stability while we monitor for any policy shifts.” Clinical Perspective Clinicians should expect minimal immediate changes to Nevada’s medical cannabis program operations or patient certification processes. However, monitoring upcoming board meetings and policy announcements remains prudent, as new leadership may eventually influence product testing standards, dispensary regulations, or patient access protocols that affect clinical recommendations. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20CCB%20Deputy%20Director%20Miles%20Appointed%20Acting%20Executive%20Director%20%40drcaplan&url=https%3A//ccb.nv.gov/ccb-welcomes-new-board-member-general-ondra-l-berry-copy-copy-copy/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//ccb.nv.gov/ccb-welcomes-new-board-member-general-ondra-l-berry-copy-copy-copy/)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20CCB%20Deputy%20Director%20Miles%20Appointed%20Acting%20Executive%20Director%20--%20via%20%40drcaplan.bsky.social%20https%3A//ccb.nv.gov/ccb-welcomes-new-board-member-general-ondra-l-berry-copy-copy-copy/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://ccb.nv.gov/ccb-welcomes-new-board-member-general-ondra-l-berry-copy-copy-copy/](https://ccb.nv.gov/ccb-welcomes-new-board-member-general-ondra-l-berry-copy-copy-copy/) Table of Contents - [FAQ](#FAQ)[What type of clinical development does this represent?](#What_type_of_clinical_development_does_this_represent) - [What areas does this cannabis news cover?](#What_areas_does_this_cannabis_news_cover) - [Why is this classified as “Notable Clinical Interest”?](#Why_is_this_classified_as_Notable_Clinical_Interest) - [What is the significance of the CED Clinical Relevance rating system?](#What_is_the_significance_of_the_CED_Clinical_Relevance_rating_system) - [How might this affect patient access to medical cannabis?](#How_might_this_affect_patient_access_to_medical_cannabis) - [Related](#Related) ## FAQ #### What type of clinical development does this represent? This represents a notable clinical interest development with emerging findings or policy developments in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). It carries a CED Clinical Relevance rating of #70, indicating it’s worth monitoring closely for potential clinical implications. #### What areas does this cannabis news cover? The news covers multiple key areas including policy changes, medical cannabis program developments, and regulatory affairs. It also addresses patient access issues within the [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) framework. #### Why is this classified as “Notable Clinical Interest”? The classification indicates emerging findings or policy developments that could impact clinical practice. These developments are considered significant enough to warrant close monitoring by healthcare professionals and researchers. #### What is the significance of the CED Clinical Relevance rating system? The CED Clinical Relevance rating helps healthcare professionals prioritize cannabis-related developments based on their potential clinical impact. A rating of #70 suggests moderate to high relevance for clinical practice and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). #### How might this affect patient access to medical cannabis? As this involves policy, regulatory affairs, and patient access components, it likely represents changes that could either improve or modify how patients obtain medical cannabis. The specific impact would depend on the nature of the policy or regulatory changes being implemented. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “CCB Deputy Director Miles Appointed Acting Executive Director”, “url”: “https://ccb.nv.gov/ccb-welcomes-new-board-member-general-ondra-l-berry-copy-copy-copy/”, “datePublished”: “2026-03-20T05:16:02Z”, “about”: “ccb deputy director miles appointed acting”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Healey signs law restructuring [Cannabis Control Commission](https://cedclinic.com/massachusetts-cannabis-industry-shawn-collins-impact/) – Western Mass News Learn about recent legislative changes restructuring cannabis regulatory bodies and their impact on program operations. Read More [InFocus featuring Cannabis Control Commission Chair Shannon O'Brien – YouTube](https://cedclinic.com/massachusetts-medical-cannabis-regulations-patient-access/) Watch insights from the [Cannabis Control Commission](https://cedclinic.com/massachusetts-cannabis-industry-shawn-collins-impact/) Chair on regulatory priorities and patient access. [Watch Now](https://cedclinic.com/massachusetts-medical-cannabis-regulations-patient-access/) [Healey signature would give her control of Cannabis Commission](https://cedclinic.com/2026-cannabis-commission-governance-healey-control/) Explore the implications of executive control over cannabis regulatory commissions and program stability. [Explore Details](https://cedclinic.com/2026-cannabis-commission-governance-healey-control/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).